Leiden, The Netherlands — December 11, 2025 — Leads & Copy — ProteoNic BV’s 2G UNic® technology has been licensed by Ginkgo Bioworks (NYSE: DNA) for a BARDA-funded project. The project, valued at up to $22.2 million, aims to lower costs for domestic biomanufacturing of monoclonal antibodies (mAbs) to treat filovirus infections like Ebola and Sudan Virus.
Ginkgo Bioworks leads a team that includes Advanced BioScience Laboratories (ABL), Isolere Bio by Donaldson, NeuImmune, and ProteoNic. The team will integrate technologies across the mAb production process to create a cost-effective biomanufacturing solution for medical countermeasures.
ProteoNic’s 2G UNic vector and transposon technologies will be used to maximize expression and productivity in mammalian systems, enhancing manufacturing efficiency and yield.
ProteoNic CEO Frank Pieper stated that the company is proud to contribute its technology to this public health initiative, enabling more efficient biologics production globally.
The collaboration will expand ProteoNic’s reach into biologics manufacturing for therapeutic protein production, cell, and gene therapy and strengthen biomanufacturing resilience to future global health threats.
This project has been awarded through the BioMaP-Consortium, overseen by BARDA and managed by Advanced Technology International (ATI), and funded by the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); BARDA.
Jonathan Frampton, VP Business Development, frampton@proteonic.nl
Leon Melens, LifeSpring Life Sciences Communication, Netherlands, lmelens@lifespring.nl
Source: ProteoNic
